High materiality7/10
B.Riley Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
B.Riley reiterates Buy on FDMT. Target 37; posted price 14.31.
- Buy reiterated; target 37 vs 14.31
Key facts
- 01
Target: $37
- 02
Posted price: $14.31
- 03
Analyst firm: B.Riley Financial
- 04
Analyst: Mayank Mamtani
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.